Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Alnylam Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was 52.8%. For fiscal 2025 it was 8.4%, against -12.4% the year before. The highest annual figure on record is 8.4% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.4% | +20.8 |
| FY2024 | Dec 31, 2024 | -12.4% | +11.7 |
| FY2023 | Dec 31, 2023 | -24.1% | +85.0 |
| FY2022 | Dec 31, 2022 | -109.0% | −8.0 |
| FY2021 | Dec 31, 2021 | -101.0% | +73.1 |
| FY2020 | Dec 31, 2020 | -174.1% | +229.1 |
| FY2019 | Dec 31, 2019 | -403.2% | +613.3 |
| FY2018 | Dec 31, 2018 | -1016.6% | −470.6 |
| FY2017 | Dec 31, 2017 | -545.9% | +323.7 |
| FY2016 | Dec 31, 2016 | -869.6% | −826.1 |
| FY2010 | Dec 31, 2010 | -43.5% | +3.8 |
| FY2009 | Dec 31, 2009 | -47.3% | −20.0 |
| FY2008 | Dec 31, 2008 | -27.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 148.6% | +125.2 |
| Q2 FY2026 | Jun 30, 2026 | 12.7% | +22.1 |
| Q1 FY2026 | Mar 31, 2026 | 17.6% | +20.7 |
| Q4 FY2025 | Dec 31, 2025 | 10.2% | +24.3 |
| Q3 FY2025 | Sep 30, 2025 | 23.4% | +45.7 |
| Q2 FY2025 | Jun 30, 2025 | -9.3% | −6.8 |
| Q1 FY2025 | Mar 31, 2025 | -3.1% | +10.3 |
| Q4 FY2024 | Dec 31, 2024 | -14.1% | +17.2 |
| Q3 FY2024 | Sep 30, 2024 | -22.3% | −42.0 |
| Q2 FY2024 | Jun 30, 2024 | -2.6% | +84.0 |
| Q1 FY2024 | Mar 31, 2024 | -13.3% | +41.2 |
| Q4 FY2023 | Dec 31, 2023 | -31.4% | +30.6 |
| Q3 FY2023 | Sep 30, 2023 | 19.7% | +173.3 |
| Q2 FY2023 | Jun 30, 2023 | -86.6% | +36.8 |
| Q1 FY2023 | Mar 31, 2023 | -54.5% | +58.2 |
| Q4 FY2022 | Dec 31, 2022 | -61.9% | +38.0 |
| Q3 FY2022 | Sep 30, 2022 | -153.6% | −44.6 |
| Q2 FY2022 | Jun 30, 2022 | -123.4% | −37.4 |
| Q1 FY2022 | Mar 31, 2022 | -112.7% | +0.1 |
| Q4 FY2021 | Dec 31, 2021 | -100.0% | +48.9 |
| Q3 FY2021 | Sep 30, 2021 | -109.0% | +92.3 |
| Q2 FY2021 | Jun 30, 2021 | -85.9% | +86.5 |
| Q1 FY2021 | Mar 31, 2021 | -112.8% | +70.4 |
| Q4 FY2020 | Dec 31, 2020 | -148.9% | +236.4 |
| Q3 FY2020 | Sep 30, 2020 | -201.3% | +96.4 |
| Q2 FY2020 | Jun 30, 2020 | -172.4% | +318.5 |
| Q1 FY2020 | Mar 31, 2020 | -183.2% | +363.2 |
| Q4 FY2019 | Dec 31, 2019 | -385.3% | +620.0 |
| Q3 FY2019 | Sep 30, 2019 | -297.6% | +11557.5 |
| Q2 FY2019 | Jun 30, 2019 | -490.9% | +56.0 |
| Q1 FY2019 | Mar 31, 2019 | -546.4% | +98.5 |
| Q4 FY2018 | Dec 31, 2018 | -1005.3% | −630.3 |
| Q3 FY2018 | Sep 30, 2018 | -11855.1% | −11136.0 |
| Q2 FY2018 | Jun 30, 2018 | -546.9% | +196.4 |
| Q1 FY2018 | Mar 31, 2018 | -644.8% | −79.0 |
| Q4 FY2017 | Dec 31, 2017 | -375.0% | – |
| Q3 FY2017 | Sep 30, 2017 | -719.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -743.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -565.9% | – |
See a number that looks wrong?